Oxford-Led Study Shows Efficacy Of COVID-19 Vaccines Dwindles Over Time Against Delta Variant

  • COVID-19 vaccines from Pfizer Inc PFEBioNTech SE BNTX and Oxford–AstraZeneca Plc AZN have shown effectiveness against the highly infectious Delta variant of SARS-CoV-2.
  • But the protection drops away over time, a study in the U.K. has concluded.
  • Researchers analyzed a data set comprising the results of more than 2.6 million PCR tests. 
  • The results, published in a preprint on 19 August, suggest that both vaccines are effective against Delta after two doses but that the protection they offer wanes with time. 
  • Pfizer-BioNTech's vaccine was 92% effective at keeping people from developing a high viral load 14 days after the second dose. But the vaccine's effectiveness fell to 90%, 85%, and 78% after 30, 60, and 90 days, respectively.
  • Oxford-AstraZeneca shot was 69% effective against a high viral load 14 days after the second dose, falling to 61% by 90 days.
  • The data also suggest that the time between doses of vaccine doesn't affect vaccine effectiveness.
  • Related: Do mRNA COVID-19 Vaccines Cause Skin Or Kidney Disorders? EMA Investigates Possible Links.
  • Price Action: PFE shares are up 0.94% at $49.26, BNTX stock is up 6.77% at $354.27, AZN stock is up 0.50% at $59.49 during the market session on the last check Friday.
  • Photo by Johaehn from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!